Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
达格列净治疗伴有心血管代谢风险因素的COVID-19住院患者（DARE-19）：一项随机、双盲、安慰剂对照的3期试验
期刊:Lancet Diabetes & Endocrinology
影响因子:41.8
doi:10.1016/S2213-8587(21)00180-7
Kosiborod, Mikhail N; Esterline, Russell; Furtado, Remo H M; Oscarsson, Jan; Gasparyan, Samvel B; Koch, Gary G; Martinez, Felipe; Mukhtar, Omar; Verma, Subodh; Chopra, Vijay; Buenconsejo, Joan; Langkilde, Anna Maria; Ambery, Philip; Tang, Fengming; Gosch, Kensey; Windsor, Sheryl L; Akin, Emily E; Soares, Ronaldo V P; Moia, Diogo D F; Aboudara, Matthew; Hoffmann Filho, Conrado Roberto; Feitosa, Audes D M; Fonseca, Alberto; Garla, Vishnu; Gordon, Robert A; Javaheri, Ali; Jaeger, Cristiano P; Leaes, Paulo E; Nassif, Michael; Pursley, Michael; Silveira, Fabio Serra; Barroso, Weimar Kunz Sebba; Lazcano Soto, José Roberto; Nigro Maia, Lilia; Berwanger, Otavio
